Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Starling Oncology, Inc. - Common Stock (NQ:STLN)

3.620 -3.080 (-45.97%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Starling Oncology, Inc. - Common Stock

Top US Stock Gainers and Losers in Today's Session ↗
Via Chartmill
Top US Stock Gainers and Losers: Nov. 6, 2026 Session ↗
Via Chartmill
News headline image
Oncology Institute Q3 Earnings Call Highlights ↗
Oncology Institute (NASDAQ:STLN), referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy growth... 
Via MarketBeat
Topics Earnings Economy
After-Hours Market Movers for Nov. 5, 2026: Gainers and Losers ↗
Via Chartmill
News headline image
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
From Starling Oncology
Via GlobeNewswire
News headline image
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
From Starling Oncology
Via GlobeNewswire
News headline image
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums 
From Starling Oncology
Via GlobeNewswire
News headline image
Starling Oncology to Participate in Wells Fargo Healthcare Conference
From Starling Oncology
Via GlobeNewswire
News headline image
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow 
From Starling Oncology
Via GlobeNewswire
News headline image
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
From Starling Oncology
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.